Both in Pharmaceuticals
NextCure vs TransCode Therapeutics
Over the past year NXTC returned −50.7% and RNAZ returned −85.1%; their daily moves had a correlation of 0.09.
NXTC −50.7% RNAZ −85.1%Growth of $1, one year, split-adjusted
| Metric | NXTC | RNAZ |
|---|---|---|
| Price | $5.91 | $1.57 |
| Market cap | $27.1M | $26.6M |
| Today | +3.78% | −3.68% |
| 1 month | +17.0% | −10.8% |
| 6 months | −36.6% | −80.0% |
| Year to date | −58.4% | −77.0% |
| 1 year | −53.1% | — |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $20.1M | $7.7M |
| Dividend yield | — | — |
| Volatility (60d) | 111.0% | 75.6% |
| Short % of float | 8.4% | 8.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).